What does Kimia Bioscien. do?

Kimia Biosciences Ltd manufactures bulk drugs (APIs) in the Pharmaceuticals & Biotechnology industry, with a market cap of Rs 225 Cr. As of December 2024, it reported net sales of 30 Cr and a net profit of 5 Cr.

Overview: <BR>Kimia Biosciences Ltd is engaged in the manufacturing of bulk drugs (APIs) within the Pharmaceuticals & Biotechnology industry and operates in the micro-cap market.<BR><BR>History: <BR>The company was incorporated in September 1993, previously known as Laurel Organics Limited. The latest quarterly results reported net sales and profit for December 2024.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 30 Cr (Quarterly Results - Dec 2024) <BR>Most recent Net Profit: 5 Cr (Quarterly Results - Dec 2024) <BR>Market-cap value: Rs 225 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 24.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 11.22 <BR>Return on Equity: 278.70% <BR>Price to Book: 65.79<BR><BR>Contact Details: <BR>Address: Bhondsi Village, Tehsil Sohna Gurgaon Haryana : 122102 <BR>Tel: 91-11-29535650 <BR>Email: laurelorganicslimited@gmail.com <BR>Website: http://www.kimiabiosciences.com

Has Kimia Bioscien. declared dividend?

No Dividend History Available

Who are the peers of the Kimia Bioscien.?

Kimia Bioscien.'s peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Kimia has below-average management risk, growth, and capital structure compared to its peers, with a 1-year return of -4.25%.

Peers: The peers of Kimia Bioscien. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Natural Capsules, Pharmaids Pharma, Alpa Laboratorie, Panch.Organics, and Syschem (India).<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest have Good management risk. Average management risk is found at Alpa Laboratorie and Panch.Organics, while Below Average management risk is noted at Kimia Bioscien., Pharmaids Pharma, Natural Capsules, and the rest. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Kimia Bioscien., Pharmaids Pharma, Divi's Lab., Torrent Pharma, Alpa Laboratorie, Panch.Organics, and the rest. Excellent capital structure is present at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Alpa Laboratorie, while Good capital structure is found at Torrent Pharma and Natural Capsules, and Below Average capital structure is noted at Kimia Bioscien., Pharmaids Pharma, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while the lowest is Natural Capsules at -20.72%. Kimia Bioscien.'s 1-year return is -4.25%, which is higher than Natural Capsules but lower than all other peers. Additionally, the six-month return is negative for Natural Capsules, Pharmaids Pharma, Alpa Laboratorie, Panch.Organics, and Syschem (India).

What is the technical trend for Kimia Bioscien.?

As of May 22, 2025, Kimia Bioscien's trend is mildly bearish, influenced by daily moving averages indicating a bearish trend, while weekly indicators show mixed signals, leading to a neutral to mildly bearish outlook.

As of 22 May 2025, the technical trend for Kimia Bioscien has changed from bearish to mildly bearish. The current stance is mildly bearish, primarily driven by the daily moving averages indicating a bearish trend, while the weekly MACD and Bollinger Bands show mildly bullish signals. The weekly RSI remains bearish, suggesting downward pressure, while the monthly indicators present a mixed picture with no strong signals. Overall, the lack of a clear trend in the Dow Theory further supports the neutral to mildly bearish outlook.

Who are in the management team of Kimia Bioscien.?

As of March 2022, the management team of Kimia Bioscien includes Sameer Goel (Chairman & Managing Director), Jagdeep Dhavvan (Independent Director), Richa Gupta (Independent Director), Vipul Goel (Director), and Lakshay Prakash (Company Secretary & Compliance Officer). Only Sameer Goel receives remuneration, which is 60.0 lacs INR, while the others serve without pay.

As of March 2022, the management team of Kimia Bioscien includes:<BR><BR>1. Sameer Goel - Chairman & Managing Director<BR>2. Jagdeep Dhavvan - Independent Director<BR>3. Richa Gupta - Independent Director<BR>4. Vipul Goel - Director<BR>5. Lakshay Prakash - Company Secretary & Compliance Officer<BR><BR>Sameer Goel is the only member with a specified remuneration, which is 60.0 lacs INR. The other members serve in their respective roles without remuneration.

Who are the top shareholders of the Kimia Bioscien.?

The top shareholders of Kimia Bioscien include Sameer Goel with 74.94%, individual investors with 23.04%, and Anish Kumar Aggarwal as the highest public shareholder at 4.33%. There are no pledged promoter holdings or foreign institutional investors, and mutual funds hold a minor 0.38%.

The top shareholders of Kimia Bioscien include the promoters, with Sameer Goel holding the highest stake at 74.94%. There are also individual investors who collectively hold 23.04% of the shares. Additionally, Anish Kumar Aggarwal is the highest public shareholder, owning 4.33%. The company has no pledged promoter holdings and is not currently held by any foreign institutional investors. Mutual funds have a minor presence, with three schemes holding a total of 0.38%.

How big is Kimia Bioscien.?

As of 24th July, Kimia Biosciences Ltd has a market capitalization of 341.00 Cr, with recent net sales of 118.92 Cr and a net profit of 9.61 Cr. Shareholder's funds are 0.33 Cr and total assets are valued at 94.18 Cr as of March 2024.

As of 24th July, Kimia Biosciences Ltd has a market capitalization of 341.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 118.92 Cr and a Net Profit of 9.61 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 0.33 Cr and Total Assets valued at 94.18 Cr.

Are Kimia Bioscien. latest results good or bad?

Kimia Biosciences reported disappointing results for Q2 2025, with net sales down 20.7% to Rs 23.58 crore and a loss before tax of Rs 0.16 crore, indicating significant financial challenges and poor performance overall.

Kimia Biosciences has reported disappointing financial results for the quarter ending June 2025. The company's net sales decreased significantly by 20.7% compared to the previous four quarters, totaling Rs 23.58 crore. This decline is concerning, especially given that the average net sales over the prior quarters were Rs 29.73 crore.<BR><BR>Moreover, the company experienced a loss before tax of Rs 0.16 crore, which represents a drastic decline of 105.2% from the average profit of Rs 3.08 crore in earlier quarters. Profit after tax also fell sharply to Rs 0.60 crore, down 75% from the average of Rs 2.40 crore.<BR><BR>Interest expenses increased to Rs 1.75 crore, the highest in five quarters, indicating that the company is facing higher borrowing costs. The operating profit margin dropped to 10.73%, reflecting a deterioration in operational efficiency. Additionally, earnings per share fell to Rs 0.13, signaling reduced profitability for shareholders.<BR><BR>Overall, these results suggest that Kimia Biosciences is currently facing significant challenges, and the financial performance can be characterized as poor.

When is the next results date for Kimia Bioscien.?

Kimia Bioscien. will announce its results on 14 November 2025.

Kimia Bioscien. is scheduled to declare its results on 14 November 2025.

How has been the historical performance of Kimia Bioscien.?

Kimia Bioscien's historical performance has shown fluctuations, with net sales declining from a peak of 132.71 Cr in Mar'21 to 118.92 Cr in Mar'25. However, the latest fiscal year marked a recovery, with operating profit rising to 21.57 Cr and profit after tax reaching 9.61 Cr, alongside an increase in total assets.

Answer:<BR>The historical performance of Kimia Bioscien shows a fluctuating trend in net sales and profitability over the years, with a notable recovery in the latest fiscal year.<BR><BR>Breakdown:<BR>Kimia Bioscien's net sales peaked at 132.71 Cr in Mar'21 but have since declined, reaching 118.92 Cr in Mar'25. The total operating income followed a similar pattern, with a high of 132.71 Cr in Mar'21 and a decrease to 118.92 Cr in Mar'25. Raw material costs increased to 74.55 Cr in Mar'25 from 67.36 Cr in Mar'24, while total expenditure decreased to 98.67 Cr in Mar'25 from 105.36 Cr in Mar'24. Operating profit (PBDIT) showed a significant recovery, rising to 21.57 Cr in Mar'25 from a loss of 0.48 Cr in Mar'24. Profit before tax also improved to 13.63 Cr in Mar'25, compared to a loss of 7.18 Cr in Mar'24, leading to a profit after tax of 9.61 Cr in Mar'25, a recovery from a loss of 5.31 Cr in the previous year. The company's total assets increased to 109.45 Cr in Mar'25 from 94.18 Cr in Mar'24, while total liabilities also rose to 109.45 Cr from 94.18 Cr, indicating a balanced growth in both assets and liabilities. Overall, Kimia Bioscien has shown a positive turnaround in its financial performance in the latest fiscal year.

Is Kimia Bioscien. overvalued or undervalued?

As of November 17, 2025, Kimia Bioscien. is considered an attractive investment opportunity due to its undervaluation compared to peers, with a PE Ratio of 19.11, a low PEG Ratio of 0.11, and strong ROE of 82.13%, despite a year-to-date stock performance of -27.62%.

As of 17 November 2025, the valuation grade for Kimia Bioscien. has moved from fair to attractive, indicating a positive shift in its market perception. The company is currently considered undervalued, especially when compared to its peers in the pharmaceuticals and biotechnology sector. Key ratios include a PE Ratio of 19.11, an EV to EBITDA of 10.35, and an impressive ROE of 82.13%. <BR><BR>In comparison to its peers, Kimia Bioscien. stands out with a significantly lower PEG Ratio of 0.11, while Sun Pharma. is deemed expensive with a PE Ratio of 36.69 and an EV to EBITDA of 24.22. Other peers like Divi's Lab and Torrent Pharma are also classified as very expensive, with PE Ratios of 69.78 and 59.48, respectively. Despite recent stock performance lagging behind the Sensex, with a year-to-date return of -27.62% compared to the Sensex's 8.72%, the valuation metrics suggest that Kimia Bioscien. presents a compelling investment opportunity at its current price of 33.04.

Should I buy, sell or hold Kimia Bioscien.?

Which are the latest news on Kimia Bioscien.?

Why is Kimia Bioscien. falling/rising?

As of 03-Dec, Kimia Biosciences Ltd's stock price is rising to Rs 29.69, marking a 9.4% increase after a trend reversal following four days of decline. Despite a year-to-date drop of 34.96%, today's trading shows increased investor interest and potential recovery.

As of 03-Dec, Kimia Biosciences Ltd's stock price is rising, currently at Rs 29.69, reflecting a change of Rs 2.55 or 9.4% increase. This upward movement comes after a trend reversal, as the stock has gained after four consecutive days of decline. Additionally, today's performance has outperformed the sector by 9.41%. The stock reached an intraday high of Rs 29.78, indicating strong buying interest.<BR><BR>Despite the recent rise, it is important to note that the stock has experienced significant declines over longer periods, with a year-to-date decrease of 34.96% and a one-year decline of 36.36%. However, the current trading session has shown increased investor participation, with delivery volume rising by 75.78% compared to the five-day average, suggesting renewed interest from investors.<BR><BR>The stock has also exhibited high volatility today, with an intraday volatility of 5.45%. Although it is trading below its moving averages across various time frames, the current price action indicates a potential recovery phase, supported by the increased trading volume and positive performance relative to the sector.